 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...475476477478479480481482483484485...522523» |
- | cisplatin / Generic mfg.
Journal: Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy. (Pubmed Central) - Apr 20, 2017
The results suggest that four cycles of neoadjuvant GC may be superior to three cycles, and the latter regimen may be associated with adverse pathological findings. Although this would require validation in a prospective trial, it does encourage the completion of the conventional four cycles GC whenever possible.
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
Journal: Breast implant-associated anaplastic large-cell lymphoma and the role of brentuximab vedotin (SGN-35) therapy: A case report and review of the literature. (Pubmed Central) - Apr 19, 2017
The patient completed three cycles of combination chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP regimen) followed by radiation consolidation therapy, and has maintained a complete remission ever since. The aim of the present study was to review the treatment options for BIA ALCL and suggest an investigation of the CD30-directed antibody-drug conjugate, brentuximab vedotin, as a potential treatment option for BIA ALCL.
- | Zevalin (ibritumomab tiuxetan) / Spectrum Pharma, Servier, Mundipharma
Journal: Phase 2 study of CHOP-R-14 followed by (90)Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma. (Pubmed Central) - Apr 19, 2017
Hematological adverse events were common following CHOP-R-14 and RIT, but they were manageable with treatment interruption. Therefore, this regimen achieved promising survival outcomes in high-risk DLBCL on long term follow-up, with manageable toxicity.
- | Decadron (dexamethasone) / Merck (MSD)
Trial primary completion date: Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (clinicaltrials.gov) - Apr 19, 2017
P2, N=100, Recruiting, Sponsor: University of Arkansas
Therefore, this regimen achieved promising survival outcomes in high-risk DLBCL on long term follow-up, with manageable toxicity. Trial primary completion date: Mar 2017 --> Mar 2018
- | doxorubicin hydrochloride / Generic mfg.
Journal: In situ biodegradable crosslinking of cationic oligomer coating on mesoporous silica nanoparticles for drug delivery. (Pubmed Central) - Apr 19, 2017
In this study, we demonstrate a simple approach to developing mesoporous nanohybrids via a process of pre-drug loading (using doxorubicin (DOX) as a model drug) into mesoporous silica nanoparticles (MSN), followed by surface functionalization with a kind of cationic oligomer (low molecular weight polyethylene imine, LPEI) and in situ crosslinking by degradable N,N'-bis(acryloyl)cystamine (BAC)...The nanohybrids displayed a pH- and redox-dual sensitivity in DOX release under conditions that mimic intracellular reductive conditions and acidic tumor microenvironments. The nanohybrids can be effectively internalized into A549 cells (a carcinomic human alveolar basal epithelial cell line), resulting in a high DOX intracellular accumulation and an improved anticancer cytotoxicity when compared with free DOX, suggesting their high potential as a new platform for therapeutic delivery.
- |||||||||| thioguanine / Generic mfg.
New P2/3 trial, IO biomarker: Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma (clinicaltrials.gov) - Apr 17, 2017
P2/3, N=1000, Recruiting, Sponsor: St. Jude Children's Research Hospital
- | doxorubicin hydrochloride / Generic mfg.
New P3 trial, Metastases: TACE-EBRT: A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC (clinicaltrials.gov) - Apr 17, 2017
P3, N=300, Recruiting, Sponsor: Shanghai Zhongshan Hospital
- |||||| Halpryza (rituximab biosimilar) / Innovent Biologics, Eli Lilly
Enrollment open, Combination therapy: A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients (clinicaltrials.gov) - Apr 16, 2017
P3, N=400, Recruiting, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
The nanohybrids can be effectively internalized into A549 cells (a carcinomic human alveolar basal epithelial cell line), resulting in a high DOX intracellular accumulation and an improved anticancer cytotoxicity when compared with free DOX, suggesting their high potential as a new platform for therapeutic delivery. Not yet recruiting --> Recruiting
- | doxorubicin hydrochloride / Generic mfg.
Journal: Folic acid-modified soy protein nanoparticles for enhanced targeting and inhibitory. (Pubmed Central) - Apr 15, 2017
Doxorubicin (DOX) was then successfully loaded into SP and FA-SP NPs with a desirable loading content of 13.33% and 16.01%, respectively...In vivo, tumor accumulation and growth inhibitory were then examined using H22 tumor-bearing mice. All these results demonstrated that conjugation of FA can efficiently enhance SP-based NPs' tumor accumulation and antitumor effect.
- || Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 13, 2017
P2, N=100, Recruiting, Sponsor: M.D. Anderson Cancer Center
All these results demonstrated that conjugation of FA can efficiently enhance SP-based NPs' tumor accumulation and antitumor effect. Trial primary completion date: Oct 2018 --> Oct 2019
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
New P2 trial: P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov) - Apr 13, 2017
P2, N=44, Not yet recruiting, Sponsor: City of Hope Medical Center
- | Kisqali (ribociclib) / Novartis
Enrollment open, Combination therapy, Surgery, Metastases: Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery (clinicaltrials.gov) - Apr 12, 2017
P1b, N=36, Recruiting, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: Oct 2018 --> Oct 2019 Not yet recruiting --> Recruiting
- | doxorubicin hydrochloride / Generic mfg.
New P1 trial: Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children (clinicaltrials.gov) - Apr 12, 2017
P1, N=28, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Trial primary completion date: AHOD0031: Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease (clinicaltrials.gov) - Apr 12, 2017
P3, N=1734, Completed, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2012 --> Aug 2012
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Avastin (bevacizumab) / Roche, Neulasta (pegfilgrastim) / Roche
Trial initiation date, Surgery: Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy (clinicaltrials.gov) - Apr 11, 2017
P2, N=100, Recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Mar 2012 --> Aug 2012 Initiation date: Jun 2013 --> Dec 2013
- | Decadron (dexamethasone) / Merck (MSD), Oncaspar liquid (pegaspargase) / Servier
Enrollment change, Trial termination, Trial primary completion date: NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 11, 2017
P2, N=23, Terminated, Sponsor: St. Jude Children's Research Hospital
Initiation date: Jun 2013 --> Dec 2013 N=72 --> 23 | Recruiting --> Terminated | Trial primary completion date: May 2027 --> Jun 2021
- ||||| thioguanine / Generic mfg.
Enrollment closed, Trial primary completion date: Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 11, 2017
P3, N=600, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
N=72 --> 23 | Recruiting --> Terminated | Trial primary completion date: May 2027 --> Jun 2021 Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2019 --> Nov 2020
- | Trial primary completion date: Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL (clinicaltrials.gov) - Apr 11, 2017
P2, N=134, Recruiting, Sponsor: Samsung Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2019 --> Nov 2020 Trial primary completion date: Dec 2017 --> Dec 2019
- | Rituxan (rituximab) / Roche
Enrollment open: Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma (clinicaltrials.gov) - Apr 11, 2017
P1/2, N=36, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2017 --> Dec 2019 Not yet recruiting --> Recruiting
- | doxorubicin hydrochloride / Generic mfg.
New trial, Combination therapy: ISP-TACE Versus TACE for HCC With PVTT (clinicaltrials.gov) - Apr 10, 2017
P=N/A, N=126, Completed, Sponsor: Zhongda Hospital
- | propranolol / Generic mfg.
New P2 trial, Metastases: Use of Propranolol Hydrochloride in the Treatment of Metastatic STS (clinicaltrials.gov) - Apr 10, 2017
P2, N=50, Not yet recruiting, Sponsor: Ain Shams University
- | paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Biomarker, Trial completion: Neoadjuvant Chemotherapy Using Doxorubicin and Paclitaxel in Treating Women With Large Breast Cancer (clinicaltrials.gov) - Apr 10, 2017
P2, N=62, Completed, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Journal: Pharmacokinetics and pharmacodynamics evaluation of a thermosensitive chitosan based hydrogel containing liposomal doxorubicin. (Pubmed Central) - Apr 8, 2017
In addition, the lower distribution index (the ratio of AUC of normal tissue/AUC of tumor tissue) of the LipDOX+C/GP implied it had lower toxicity to normal tissues than DOX+C/GP. Therefore, the novel thermosensitive hydrogel formulation was potential for clinical application in cancer treatment.
- | doxorubicin hydrochloride / Generic mfg.
Journal: 3-Carboxyphenylboronic acid-modified carboxymethyl chitosan nanoparticles for improved tumor targeting and inhibitory. (Pubmed Central) - Apr 8, 2017
Doxorubicin (DOX) as a model drug was successfully encapsulated to give CM-DOX and CB-DOX NPs...CB-DOX NPs can deliver more drug than CM-DOX NPs, and retain for a long time in lung tissue, thus remarkably reducing the size of tumor mass of H22 metastasis lung tumor. All results demonstrate that the obtained NPs would be potentially useful as nano-scaled drug carriers in chemotherapy.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (clinicaltrials.gov) - Apr 7, 2017
P2, N=18, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
All results demonstrate that the obtained NPs would be potentially useful as nano-scaled drug carriers in chemotherapy. Recruiting --> Active, not recruiting | N=28 --> 18 | Trial primary completion date: Dec 2017 --> Dec 2018
- | bortezomib / Generic mfg.
Trial completion, Enrollment change: Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment (clinicaltrials.gov) - Apr 7, 2017
P2, N=46, Completed, Sponsor: Guido Tricot
Recruiting --> Active, not recruiting | N=28 --> 18 | Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed | N=204 --> 46
- | Xalkori (crizotinib) / Pfizer, Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial suspension, Combination therapy: Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma (clinicaltrials.gov) - Apr 7, 2017
P2, N=140, Suspended, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=204 --> 46 Recruiting --> Suspended
- | Trial initiation date, Combination therapy, IO biomarker: Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma (clinicaltrials.gov) - Apr 7, 2017
P2, N=26, Recruiting, Sponsor: University of Miami
Recruiting --> Suspended Initiation date: Apr 2011 --> Apr 2009
- Rituxan (rituximab) / Roche
Trial primary completion date: Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Apr 7, 2017
P2, N=45, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Initiation date: Apr 2011 --> Apr 2009 Trial primary completion date: Dec 2017 --> Dec 2018
- ||| Gazyva (obinutuzumab) / Roche, Biogen
Enrollment closed: A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Apr 7, 2017
P1/2, N=59, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting
- ||| Nerlynx (neratinib) / Puma, Perjeta (pertuzumab) / Roche
New P1 trial, Metastases: Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Apr 5, 2017
P1b, N=99, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Trial initiation date: Mature B-Cell Lymphoma And Leukemia Study III (clinicaltrials.gov) - Apr 4, 2017
P2/3, N=122, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting Initiation date: Jan 2009 --> Sep 2010
- |||| Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) / Roche, Halozyme
Trial primary completion date: A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (clinicaltrials.gov) - Apr 4, 2017
P3, N=174, Active, not recruiting, Sponsor: Hoffmann-La Roche
Initiation date: Jan 2009 --> Sep 2010 Trial primary completion date: Sep 2018 --> Nov 2018
- |||| Arzerra (ofatumumab) / Novartis, Genmab
Enrollment open, Combination therapy: Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Apr 4, 2017
P2, N=80, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2018 --> Nov 2018 Active, not recruiting --> Recruiting
- || Opdivo (nivolumab) / BMS
Trial primary completion date: CheckMate 205: Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) (clinicaltrials.gov) - Apr 4, 2017
P2, N=294, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Recruiting Trial primary completion date: Jan 2017 --> Aug 2017
- | metformin / Generic mfg.
Trial primary completion date, Metastases: MBC1: Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer. (clinicaltrials.gov) - Apr 4, 2017
P2, N=96, Recruiting, Sponsor: Petrov Research Institute of Oncology
Trial primary completion date: Jan 2017 --> Aug 2017 Trial primary completion date: Nov 2015 --> Aug 2017
- | New trial: PIPAC_01: Register Study of Patients With Peritoneal Carcinomatosis Treated With PIPAC (Pressurized Intra-peritoneal Aerosol-Chemotherapy) (clinicaltrials.gov) - Apr 4, 2017
P=N/A, N=500, Recruiting, Sponsor: University of Leipzig
- | Vesanoid (tretinoin) / Roche, entinostat (SNDX-275) / Kyowa Kirin, Syndax Pharma
Journal: Combined treatment with epigenetic, differentiating, and chemotherapeutic agents cooperatively targets tumor-initiating cells in triple negative breast cancer. (Pubmed Central) - Apr 2, 2017
In this study, we found that combined treatment of TNBC xenografts with entinostat, ATRA, and doxorubicin (EAD) resulted in significant tumor regression and restoration of epigenetically silenced RAR-β expression...Finally, we demonstrate that patient-derived metastatic cells also responded to treatment with EAD. Collectively, our findings strongly suggest that entinostat potentiates doxorubicin-mediated cytotoxicity and retinoid-driven differentiation to achieve significant tumor regression in TNBC.
- | sirolimus / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Journal: Doxorubicin Regulates Autophagy Signals via Accumulation of Cytosolic Ca(2+) in Human Cardiac Progenitor Cells. (Pubmed Central) - Apr 2, 2017
Additionally, DOXO significantly induced mTOR expression in hCPCs, and inhibition of mTOR signaling by rapamycin, a specific inhibitor, rescued DOXO-mediated autophagosome depletion in hCPCs with significant reduction of DOXO-mediated cytosolic Ca(2+) accumulation in hCPCs, and restored SMP30 and mTOR expression. Thus, DOXO-mediated hCPC toxicity is linked to Ca(2+)-related autophagy signaling, and inhibition of mTOR signaling may provide a cardio-protective effect against DOXO-mediated hCPC toxicity.
- Trial termination, Trial primary completion date: Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer (clinicaltrials.gov) - Mar 31, 2017
P1, N=27, Terminated, Sponsor: University of Utah
Thus, DOXO-mediated hCPC toxicity is linked to Ca(2+)-related autophagy signaling, and inhibition of mTOR signaling may provide a cardio-protective effect against DOXO-mediated hCPC toxicity. Active, not recruiting --> Terminated | Trial primary completion date: Mar 2020 --> Mar 2017; Drug Manufacturer withdrew support for studies not in metastatic breast cancer
- | Trial initiation date: Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma (clinicaltrials.gov) - Mar 31, 2017
P2, N=80, Recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Terminated | Trial primary completion date: Mar 2020 --> Mar 2017; Drug Manufacturer withdrew support for studies not in metastatic breast cancer Initiation date: Feb 2009 --> Jun 2009
- ||| Avastin (bevacizumab) / Roche
Enrollment change: Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer (clinicaltrials.gov) - Mar 31, 2017
P2, N=51, Active, not recruiting, Sponsor: Massachusetts General Hospital
Initiation date: Feb 2009 --> Jun 2009 N=40 --> 51
- || Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial initiation date, Metastases: C25004: A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma (clinicaltrials.gov) - Mar 31, 2017
P1, N=55, Not yet recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
N=40 --> 51 Initiation date: Feb 2017 --> Jul 2017
- | bortezomib / Generic mfg.
Enrollment closed, Combination therapy: Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 30, 2017
P2, N=18, Active, not recruiting, Sponsor: Stanford University
Initiation date: Feb 2017 --> Jul 2017 Recruiting --> Active, not recruiting
- ||| Arzerra (ofatumumab) / Novartis, Genmab
Enrollment closed, Trial primary completion date, Combination therapy: Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Mar 30, 2017
P2, N=70, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2018 --> Jul 2019
- | Rituxan (rituximab) / Roche
Enrollment open: Treatment and Natural History Study of Lymphomatoid Granulomatosis (clinicaltrials.gov) - Mar 29, 2017
P2, N=90, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2018 --> Jul 2019 Suspended --> Recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Enrollment open: Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Mar 28, 2017
P2, N=50, Recruiting, Sponsor: Amgen
Suspended --> Recruiting Not yet recruiting --> Recruiting
- || bortezomib / Generic mfg., doxorubicin hydrochloride / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Bortezomib with Gemcitabine/Doxorubicin in Patients with Urothelial Cancer and Other Solid Tumors (clinicaltrials.gov) - Mar 27, 2017
P1, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2017 --> Sep 2018
- || dasatinib / Generic mfg.
Trial primary completion date: Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. (clinicaltrials.gov) - Mar 27, 2017
P2, N=115, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Sep 2017 --> Sep 2018 Trial primary completion date: Aug 2017 --> Aug 2018
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Enrollment change, Trial primary completion date, Metastases: FOLL12: Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma (clinicaltrials.gov) - Mar 27, 2017
P3, N=810, Recruiting, Sponsor: Fondazione Italiana Linfomi ONLUS
Trial primary completion date: Aug 2017 --> Aug 2018 N=602 --> 810 | Trial primary completion date: Dec 2016 --> Dec 2017